New siRNA drug aims to tame kidney disease
NCT ID NCT06989359
First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 4 times
Summary
This Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe and can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADX-038 (siRNA drug)
- What this could lead to
- If successful, this could lead to a new treatment option that helps control complement-mediated kidney diseases, potentially slowing disease progression and reducing symptoms.
- What could go wrong
- This is an early Phase 2 trial with only 45 participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3G are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
ADARx Clinical Site
RECRUITINGDoral, Florida, 33122, United States
-
ADARx Clinical Site
RECRUITINGMiami, Florida, 33127, United States
-
ADARx Clinical Site
RECRUITINGPembroke Pines, Florida, 33029, United States
-
ADARx Clinical Site
RECRUITINGIowa City, Iowa, 52242, United States
-
ADARx Clinical Site
RECRUITINGShreveport, Louisiana, 71101, United States
-
ADARx Clinical Site
RECRUITINGShelby, Michigan, 48315, United States
-
ADARx Clinical Site
RECRUITINGGreat Neck, New York, 11021, United States
-
ADARx Clinical Site
RECRUITINGColumbus, Ohio, 43210, United States
-
ADARx Clinical Site
RECRUITINGDakota Dunes, South Dakota, 57049, United States
-
ADARx Clinical Site
RECRUITINGDallas, Texas, 75230, United States
-
ADARx Clinical Site
RECRUITINGHouston, Texas, 77027, United States
-
ADARx Clinical Site
RECRUITINGLiverpool, New South Wales, 2170, Australia
-
ADARx Clinical Site
RECRUITINGWollongong, New South Wales, 2500, Australia
-
ADARx Clinical Site
RECRUITINGSydney, NSW 2139, Australia
-
ADARx Clinical Site
RECRUITINGWoolloongabba, QLD 4102, Australia
-
ADARx Clinical Site
RECRUITINGHong Kong, 2500, Hong Kong
-
ADARx Clinical Site
RECRUITINGShatin, Hong Kong
-
ADARx Clinical Site
RECRUITINGBergamo, 24020, Italy
-
ADARx Clinical Site
RECRUITINGPavia, 27100, Italy
-
ADARx Clinical Site
RECRUITINGWŏnju, Gangwon-do, 26426, South Korea
-
ADARx Clinical Site
RECRUITINGGyeonggi-do, Gurogu, 16499, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, Gurogu, 08308, South Korea
-
ADARx Clinical Site
RECRUITINGCheonan, 31151, South Korea
-
ADARx Clinical Site
RECRUITINGDaegu, 42601, South Korea
-
ADARx Clinical Site
RECRUITINGGyeonggi-do, 05278, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 02841, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 03080, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 03722, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 05278, South Korea
-
ADARx Clinical Site
RECRUITINGBarcelona, 08035, Spain
-
ADARx Clinical Site
RECRUITINGMadrid, 28041, Spain
-
ADARx Clinical Site
RECRUITINGSeville, 41009, Spain
-
ADARx Clinical Site
RECRUITINGNew Taipei City, 110, Taiwan
-
ADARx Clinical Site
RECRUITINGNewcastle upon Tyne, UK, NE7 7DN, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease